Drugs / ActHIB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01578070 | Mar → Dec 2012 | — | Viscogel AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00129129 | Aug 2004 → Sep 2005 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00359983 | Sep 2006 → Nov 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00255047 | Nov 2005 → Jul 2008 | diphtheria, pertussis, poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00197236 | Nov 2003 → Dec 2007 | hepatitis A virus infection | GlaxoSmithKline | Completed | No outcome recorded |
| Comparator or background therapy16 trials | ||||||
| Phase 2 | NCT02140047 Comparator | Apr 2014 → Jan 2015 | haemophilus infectious disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01732198 Comparator | Mar 2013 → Jan 2014 | infectious disease | Nuron Biotech Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00134719 Comparator | Apr 2005 → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00127855 Comparator | Mar 2003 → Feb 2004 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02806284 Comparator | Jan 2001 → Jan 2008 | meningitis | Uppsala University | Completed | No outcome recorded |
| Phase 3 | NCT03891758 Comparator | Apr → Sep 2019 | bacterial meningitis, diphtheria, pertussis, poliomyelitis +1 | Tanabe Pharma Corporation | Completed | Met primary |
| Phase 3 | NCT02560272 Comparator | Sep 2014 → Dec 2015 | haemophilus infectious disease | Beijing Minhai Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT02096263 Comparator | Apr 2014 → Feb 2015 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01379846 Comparator | Jun 2011 → Feb 2013 | — | Takeda | Completed | Met primary |
| Phase 3 | NCT01337167 Comparator | Apr 2011 → May 2013 | bacterial infectious disease, viral infectious disease | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 3 | NCT01214889 Comparator | Sep 2010 → Nov 2011 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | Met primary |
| Phase 3 | NCT01000974 Comparator | Jun 2010 → Nov 2011 | haemophilus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00614614 Comparator | Feb 2008 → Jul 2009 | meningococcal infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00453570 Comparator | Mar 2007 → Dec 2008 | diphtheria, haemophilus infectious disease, pertussis, poliomyelitis +1 | Sanofi | Completed | Met primary |
| Phase 3 | NCT00345579 Comparator | Sep 2006 → Oct 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00289783 Comparator | Feb 2006 → Aug 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Act-HIB | “Infants (N=792) were randomly assigned to receive DTaP-IPV//PRP-T at 2, 3 and 4 months of age (Group A) or 3, 4 and 5 months of age (Group B), or DTaP (Wuhan Institute of...” PMID 21219984 ↗ Jan 201122“Subjects received Infanrix co-administered with ActHIB at Day 0, followed by one dose of Havix at Day 30” NCT00197236 ↗ “concomitant vaccination with ActHIB® (Hib) and Tetrabik (DPT-IPV) as a comparator” PMID 38582691 ↗ Apr 2024 “0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.” NCT01578070 ↗ “using ActHIB® as a control” NCT02140047 ↗ |
| Known as | PRP-T | “Infants (N=792) were randomly assigned to receive DTaP-IPV//PRP-T at 2, 3 and 4 months of age (Group A) or 3, 4 and 5 months of age (Group B), or DTaP (Wuhan Institute of...” PMID 21219984 ↗ Jan 2011 |
| Modality | Vaccine | “licensed Hib conjugate vaccine” NCT00127855 ↗ |
| Route | Intramuscular | “Three doses were administered IM in left thigh at Months 0,2 and 4.” NCT00127855 ↗ |